House PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, et

Property PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, et al. Knowledge of malignancies with oral glucose-lowering drugs inside the randomised controlled ADOPT and RECORD clinical trials. Diabetologia. 53: 18381845. 28. Greenland S Quantitative strategies in the assessment of epidemiologic literature. Epidemiol Rev. 9: 130. 29. Higgins JP, Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med. 21: 15391558. 30. Mantel N, Haenszel W Statistical aspects from the evaluation of information from retrospective research of Arg8-vasopressin web illness. J Natl Cancer Inst. 22: 719748. 31. DerSimonian R, Laird N Meta-analysis in clinical trials. Handle Clin Trials. 7: 177188. 32. Egger M, Smith GD Bias in location and selection of research. BMJ.316: 6166. 33. Luo J, Chlebowski R, Wactawski-Wende J, Schlecht NF, Tinker L, et al. Diabetes and lung cancer among postmenopausal females. Diabetes Care. 35: 14851491. 34. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, et al. Association of thiazolidinediones with liver cancer and colorectal cancer in form 2 diabetes mellitus. Hepatology. 55: 14621472. 35. Libby G, Donnelly LA, Donnan PT, Oltipraz price Alessi DR, Morris AD, et al. New customers of metformin are at low threat of incident cancer: a cohort study among folks with variety 2 diabetes. Diabetes Care. 32: 16201625. 36. Schiel R, Muller UA, Braun A, Stein G, Kath R Risk of malignancies in sufferers with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up. Eur J Med Res. 10: 339344. 37. Vallarino C, Perez A, Fusco G, Liang H, Bron M, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, employing propensity score weights. Clinical Drug Investigation. 33: 621 631. 9 Hypoglycaemic Agents and Risk of Lung Cancer 38. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM Oral insulin secretagogues, insulin, and cancer danger in kind 2 diabetes mellitus. J Clin Endocrinol Metab. 97: E11701175. 39. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, et al. The influence of form 2 diabetes and glucose-lowering therapies on cancer danger within the Taiwanese. Exp Diabetes Res. 2012: 413782. 40. Wu N, Gu C, Gu H, Hu H, Han Y, et al. Metformin induces apoptosis of lung cancer cells by way of activating JNK/p38 MAPK pathway and GADD153. Neoplasma. 58: 482490. 41. Salani B, Maffioli S, Hamoudane M, Parodi A, Ravera S, et al. Caveolin1 is crucial for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. FASEB J. 26: 788798. 42. Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, et al. Inhibition of lung tumorigenesis by metformin is connected with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res. 6: 801810. 43. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, et al. 1846921 The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 310: 16421646. 44. Berger J, Moller DE The mechanisms of action of PPARs. Annu Rev Med. 53: 409435. 45. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, et al. Peroxisome proliferator-activated receptor-gamma ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic nonsmall-cell lung cancer cells. Oncogene. 24: 14121422. 46. Chang TH, Szabo E Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer research. 60: 11291138. 47. Qian X, Li J, Ding J, Wang Z, Duan L, et al. Glibenclamide exerts an an.Household PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, et al. Practical experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT and RECORD clinical trials. Diabetologia. 53: 18381845. 28. Greenland S Quantitative methods inside the review of epidemiologic literature. Epidemiol Rev. 9: 130. 29. Higgins JP, Thompson SG Quantifying heterogeneity inside a meta-analysis. Stat Med. 21: 15391558. 30. Mantel N, Haenszel W Statistical elements of the analysis of data from retrospective research of disease. J Natl Cancer Inst. 22: 719748. 31. DerSimonian R, Laird N Meta-analysis in clinical trials. Handle Clin Trials. 7: 177188. 32. Egger M, Smith GD Bias in location and collection of studies. BMJ.316: 6166. 33. Luo J, Chlebowski R, Wactawski-Wende J, Schlecht NF, Tinker L, et al. Diabetes and lung cancer amongst postmenopausal girls. Diabetes Care. 35: 14851491. 34. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, et al. Association of thiazolidinediones with liver cancer and colorectal cancer in form 2 diabetes mellitus. Hepatology. 55: 14621472. 35. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, et al. New customers of metformin are at low risk of incident cancer: a cohort study among individuals with kind 2 diabetes. Diabetes Care. 32: 16201625. 36. Schiel R, Muller UA, Braun A, Stein G, Kath R Danger of malignancies in sufferers with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up. Eur J Med Res. 10: 339344. 37. Vallarino C, Perez A, Fusco G, Liang H, Bron M, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, utilizing propensity score weights. Clinical Drug Investigation. 33: 621 631. 9 Hypoglycaemic Agents and Danger of Lung Cancer 38. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM Oral insulin secretagogues, insulin, and cancer threat in form 2 diabetes mellitus. J Clin Endocrinol Metab. 97: E11701175. 39. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, et al. The influence of sort 2 diabetes and glucose-lowering therapies on cancer risk within the Taiwanese. Exp Diabetes Res. 2012: 413782. 40. Wu N, Gu C, Gu H, Hu H, Han Y, et al. Metformin induces apoptosis of lung cancer cells by means of activating JNK/p38 MAPK pathway and GADD153. Neoplasma. 58: 482490. 41. Salani B, Maffioli S, Hamoudane M, Parodi A, Ravera S, et al. Caveolin1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. FASEB J. 26: 788798. 42. Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, et al. Inhibition of lung tumorigenesis by metformin is linked with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res. 6: 801810. 43. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, et al. 1846921 The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 310: 16421646. 44. Berger J, Moller DE The mechanisms of action of PPARs. Annu Rev Med. 53: 409435. 45. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, et al. Peroxisome proliferator-activated receptor-gamma ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic nonsmall-cell lung cancer cells. Oncogene. 24: 14121422. 46. Chang TH, Szabo E Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer investigation. 60: 11291138. 47. Qian X, Li J, Ding J, Wang Z, Duan L, et al. Glibenclamide exerts an an.